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Early metabolic responses in temozolomide treated low-grade
glioma patients
Abstract
Amino acid transport and protein synthesis are important steps of tumor growth. We investigated the
time course of tumor metabolism in low-grade gliomas (LGG) during temozolomide chemotherapy, and
compared metabolic responses as measured with positron emission tomography (PET) with volume
responses as revealed by magnetic resonance imaging (MR). A homogeneous population of 11 patients
with progressive non-enhancing LGG was prospectively studied. Imaging was done at 6-months
intervals starting six months, and in a second series starting three months after treatment initiation. F-18
fluoro-ethyl-l-tyrosine (FET) uptake was quantified with PET as metabolically active tumor volume,
and was compared with the tumor volume on MR. Response was defined as ≥10% reduction of the
initial tumor volume. Eight patients showed metabolic responses. Already 3 months after start of
chemotherapy the active FET volumes decreased in 2 patients to a mean of 44% from baseline. First MR
volume responses were noted at 6 months. Responders showed a volume reduction to 31 ± 23% (mean ±
SD) from baseline for FET, and to 73 ± 26% for MR. The time to maximal volume reduction was 8.0 ±
4.4 months for FET, and 15.0 ± 3.0 months for MR. The initial metabolic response correlated with the
best volume response on MR (Spearman Rank P = 0.011). Deactivation of amino acid transport
represents an early indicator of chemotherapy response in LGG. Response assessment based on MR
only has to be reconsidered. The time window obtained from PET may assist for individual treatment
decisions in LGG patients.
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Abstract 
Background: Amino acid transport and protein synthesis are important steps of tumor 
growth. We investigated the time course of tumor metabolism in low-grade gliomas 
(LGG) during temozolomide chemotherapy, and compared metabolic responses as 
measured with positron emission tomography (PET) with volume responses as 
revealed by magnetic resonance imaging (MR). 
Methods: A homogeneous population of 11 patients with progressive non-enhancing 
LGG was prospectively studied. Imaging was done at 6-months intervals starting six 
months, and in a second series starting three months after treatment initiation. F-18 
fluoro-ethyl-L-tyrosine (FET) uptake was quantified with PET as metabolically active 
tumor volume, and was compared with the tumor volume on MR. Response was 
defined as ≥ 10% reduction of the initial tumor volume. 
Results: Eight patients showed metabolic responses. Already 3 months after start of 
chemotherapy the active FET volumes decreased in 2 patients to a mean of 44% 
from baseline. First MR volume responses were noted at 6 months. Responders 
showed a volume reduction to 31±23% (mean±SD) from baseline for FET, and to 
73±26% for MR. The time to maximal volume reduction was 8.0±4.4 months for FET, 
and 15.0±3.0 months for MR. The initial metabolic response correlated with the best 
volume response on MR (Spearman Rank p=0.011). 
Conclusions: Deactivation of amino acid transport represents an early indicator of 
chemotherapy response in LGG. Response assessment based on MR only has to be 
reconsidered. The time window obtained from PET may assist for individual 
treatment decisions in LGG patients. 
 
Key words: Low-grade glioma, chemotherapy, temozolomide, positron emission 
tomography, tyrosine. 
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Introduction 
Chemotherapy represents a treatment option in low-grade glioma patients (LGG) [1]. 
This may be particularly important if tumors are not amenable to gross resection or 
irradiation. Several retrospective studies have shown that chemotherapy (either 
temozolomide or PCV regimen) was active in LGG. Using magnetic resonance (MR) 
imaging chemotherapy yielded response rates up to 61% [2-6] which were mainly 
determined by Macdonald`s criteria [7], although these criteria are not validated for 
LGG. The median time to reach a morphological response in the largest series was 
12 months [4]. As many LGG grow very slowly the inhibition of tumor metabolism 
may be detected earlier than structural volume changes. Early identification of 
treatment response by molecular imaging may be promising. Positron emission 
tomography (PET) allows to quantitatively measure several biochemical and 
physiological alterations in brain tumors. Increased amino acid transport and protein 
synthesis represent essential and early steps of tumor growth [8]. In our present 
study we used PET with the radiolabeled amino acid analogue tyrosine (F-18 fluoro-
ethyl-L-tyrosine, FET) to characterize metabolic responses in LGG patients treated 
with the alkylating agent temozolomide (TMZ). 
 
Methods 
Patients. A homogeneous population of 11 patients (median age 34 years, range 23 
– 49 years, 3 female and 8 male) with progressive supratentorial LGG WHO II 
consented to participate in our study (3 oligodendrogliomas, 4 fibrillary astrocytomas 
and 4 oligoastrocytomas [9]). Progression was defined on MR as an increase in 
tumor size of >25% and/or clinical deterioration (according to the EORTC study 
protocol on low-grade gliomas, 22033-26033 [10]), and occurred at a median of 27 
months after the first tumor surgery (range 2-127 months). No patient had received 
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previous radio- or chemotherapy. We included only patients which did not show any 
gadolinium enhancement on MR as the latter may be suggestive for transformation to 
malignant glioma. The clinical data are presented in table 1. Patients received 
75mg/m2 TMZ per day over 3 weeks, followed by one week off (21q/28d=one cycle, 
according to EORTC protocol 22033-26033 [10]). Patients were scheduled to receive 
12 cycles of chemotherapy. TMZ chemotherapy was discontinued at the time of 
tumor progression or due to inacceptable side effects. Following the baseline scans 
the imaging protocol consisted of PET and MR scans at six-month intervals, starting 
after six cycles of chemotherapy in group A (n=8). Due to the magnitude of PET 
responses observed at six months in group A the first follow-up scans in three 
subsequent patients (group B, table 1) started after three cycles of chemotherapy. 
Further follow-up scans in group B patients were scheduled 9 and 15 months after 
initiation of treatment. Based on the clinical judgement several patients received 
more than 12 cycles (up to 24). The study protocol was approved by the local Ethical 
Committee. Written consent was obtained from all patients.  
Imaging. MR imaging included standard sequences on a 1.5 Tesla Siemens 
Magnetom. Amino acid imaging with PET was done with F-18-fluoro-ethyl-L-tyrosine 
(FET). 3D PET data were acquired with a whole-body PET/CT Scanner (Discovery 
LS, GE Medical Systems, Waukesha, WI, USA, 14.6 cm axial field of view, in-plane 
resolution 7 mm). FET was intravenously administered as bolus injection of 140 to 
250 MBq. FET uptake was measured on PET images acquired from 50 to 60 min 
after tracer injection [11].  
Data analysis. Quantification of PET and MR data was done using PMOD [12] on 
digitized images as described in detail in our recent publication [13]. For calculation 
of the MR tumor volume we used the FLAIR sequence which provides the best 
delineation between tumor and adjacent brain [3, 14]. Following manual outlining of 
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the tumor boundaries the areas of all tumor containing MR slices were summed up to 
yield the whole tumor volume. For quantification of the FET PET data the cerebellum 
was used as reference region. Regions of interest (ROI) covering the whole 
cerebellum were drawn for each slice. The ROI counts of all PET slices which 
contained the cerebellum were then averaged to produce the mean cerebellar FET 
uptake (counts). For tumors two measures were calculated. First, the ‘active volume’ 
(ccm) was quantified as the tumor volume containing pixels > 110% of the mean 
cerebellar FET uptake. This threshold corresponds well to the visual impression of 
active LGG [13, 15]. Second, the tumor FET uptake (counts) of the active volume 
was normalized to the mean FET uptake of the cerebellum (T:CBL ratio, unit-less). 
This uptake ratio is routinely used in nuclear medicine, and is robust with regard to 
intra- and inter-individual comparisons. For the one patient who showed no active 
FET tumor volume (#10) the T:CBL ratio was calculated using the tumor area derived 
from the MR FLAIR images. As TMZ-induced reductions of FET uptake were better 
detectable by active volumes than by T:CBL ratios, we defined treatment response 
as a ≥ 10% reduction of the initial tumor volume (active PET, MR FLAIR) on at least 
two subsequent time points after the initiation of chemotherapy. Defining treatment 
response as a 20% volume reduction produced the same number of metabolic, but a 
lower number of MR responders. The Spearman rank test (SPSS, version 10.0.7) 
was applied to test whether baseline tumor FET uptake, or metabolic responses 
during treatment, were correlated with treatment response on MR. 
 
Results 
In total 172 cycles of TMZ were administered (mean 16, range 6-24 per patient). The 
initially scheduled TMZ dose could be maintained in 9 patients, in the two other 
patients the dose had to be reduced by 20% and 30% resp. due to hematotoxicity 
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(CTCAE v3.0, grade 2 and 3). In group A 3 patients completed 4 follow-up PET-MR 
scans, 3 patients completed 3 scans, and 2 patients completed 1 scan. In group B 
each 1 patient completed 4, 3, and 2 follow-up scans. 
Tumor volumes. At baseline a variable active FET tumor volume was found in 10/11 
patients (range 6-273ccm). This is line with earlier reports which describe a lack of 
increased amino acid uptake in a proportion of LGG [16]. The absolute numbers of 
the baseline active FET and MR volumes are presented in table 1. Overall 8/11 
patients were metabolic responders. Among these only five patients also showed a 
MR volume response (table 1). Examples of individual responses are presented in 
figures 1 and 2. At three months 2/3 patients (group B, #1, 5) showed a substantially 
reduced active FET volume (38% and 49% of baseline volume), whereas no MR 
volume change was observed. In one patient the metabolic response persisted until 
15 months (#5, figure 1c and bottom figure 2). At that time also a small volume 
response was noted on MR (90% of baseline). In group A patients (first follow-up 
study at six months) 6/8 patients showed a reduced active FET volume (range 7 to 
71% of baseline volume). At that time 4/8 MR volume reductions were observed. The 
delay between FET and MR volume reductions is illustrated in figure 3. Whereas the 
maximal reduction of the active FET volume was observed between 3 and 12 months 
(8.0±4.4, mean±SD), the delay to maximum MR volume reduction was 15.0±3.0 
months. The best FET response reached a mean of 31±23% from baseline (table 1), 
whereas the best volume response on MR reached a mean of 73±26% from 
baseline. 
Uptake ratios. The range of baseline FET T:CBL ratios was 1.10-1.64 (table 1). In 
responders the maximal reduction of FET uptake ratios was 76% from baseline. 
Similar to the active volume the maximal response of FET uptake ratios was reached 
until 12 months. 
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Response prediction. Before treatment neither the active tumor volume nor the 
uptake ratio predicted the response to TMZ chemotherapy (Spearman rank p>0.68). 
However, the FET volume response measured at the time of the first follow up study 
correlated with the best MR volume response obtained later during the course of 
chemotherapy (Spearman Rank 0.731, p=0.01, figure 4). Vice versa, patients who 
did not show a reduction of the active FET volume in their first follow up study also 
did not show PET or MR responses at later time points. With regard to tumor 
histology 6/7 oligodendroglial tumors showed a FET volume response, and 5/7 a MR 
volume response. 2/4 fibrillary astrocytomas showed a FET volume responses in the 
absence of any MR volume response. The magnitude of metabolic responses did not 
correspond to the duration of chemotherapy. 
Clinical follow up, tumor progression. A clinical benefit emerged for two patients 
which were seizure-free after four and six months of chemotherapy respectively. 
Those patients with PET and MR responses showed the longest progression-free 
survival (PFS; 38±3 months). At the time of last follow up 3/8 metabolic responders 
were still free of progression.  In patients without MR response variable PFS periods 
were noted (15±8 months). 5/8 metabolic responders progressed 19±7 months after 
initiation of chemotherapy. Four progressive patients underwent re-operation 
between 6 and 21 months after initiation of chemotherapy, which yielded unchanged 
histology (#8), anaplastic oligoastrocytoma WHO III (#5), anaplastic astrocytoma 
(#9), and glioblastoma WHO IV (#2). In those three patients with progression towards 
WHO grade III or IV a prominent increase particularly of the uptake ratio was 
observed (1.98, 1.37, 1.69 compared to an uptake ratio of 1.24, 1.24, 1.16 at best 
response). Also the active FET volume increased (28, 47, 23 ccm compared to 6, 3, 
8 ccm at best response). This is examplified by figure 1c and bottom panel of figure 
2.  
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Discussion 
LGG tend to grow slowly. A mean tumor diameter increase of 4.1mm per year was 
reported in oligodendrogliomas or mixed gliomas on serial MR [17]. TMZ 
chemotherapy reversed this increase and led to an average tumor diameter decrease 
of 9.1 mm per year in one series [18]. The key finding of our study is that a 
substantial proportion of patients initially showing stable MR volumes are ‘early’ 
metabolic responders during chemotherapy, and that metabolic responses are more 
pronounced than MR volume responses. Of note none of the patients included in our 
series showed blood-brain barrier disruption as revealed by gadolinium enhanced 
MR. Interestingly, not only oligodendroglial tumors but also fibrillary astrocytomas 
showed metabolic responses, which preceded MR volume reductions by several 
months. These responses were particularly evident from the reduction of the active 
FET tumor volume. In contrast, the uptake indices (T:CBL ratios) in responders 
decreased only slightly. This suggests a decrease in tumor cell density, and indicates 
that the residual viable tumor has a metabolic activity similar to the untreated tumor, 
which is compatible with an unchanged histology and WHO tumor grade during 
chemotherapy. 
Discrepancies between changes in amino acid uptake (C-11 methionine) and MR 
volume reductions were also reported in pure oligodendrogliomas WHO II [15]. That 
study addressed the magnitude of metabolic and MR volume response after 
completion of 4 to 6 cycles of PCV chemotherapy, and also found that responses are 
more pronounced on metabolic compared to MR imaging. Various other treatment 
modalities also produced reductions of amino acid uptake in LGG (radio-
chemotherapy [19], external beam radiotherapy [20], interstitial brachytherapy with 
I125-Iodine seeds [21]). Extrapolating our data in responding patients toward earlier 
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time points (figure 3) suggests that metabolic responses may be observed as early 
as one month after treatment initiation. Vice versa we also found that tumor 
progression was earlier evident on metabolic imaging compared with MR (figure 1c 
and bottom figure 2). Our data therefore underline the role of PET imaging with 
amino acids as a sensitive tool for early response assessment in LGG.  
Upregulation of amino acid transporters in human astrocytomas can be 
demonstrated by immunohistochemistry and correlates with the WHO grade [22, 23]. 
In accordance, increased amino acid transport as measured in vivo with PET also 
correlates with the WHO grade of gliomas [24, 25]. The importance of amino acid 
transport for tumor growth is illustrated by experiments which show that specific 
transport inhibitors produce a rapid suppression of cell growth, and prolong survival 
of rats treated with C6 glioma cells [22]. Also successful chemotherapy with the 
alkylating agent TMZ decreases amino acid transport as shown in our study. As long 
as amino acid transport was deactivated no tumor progression was evident. 
Moreover, volume expansion on MR as sign of tumor progression was paralleled by 
substantially increased amino acid transport (figure 1c and bottom figure 2). These 
findings suggest that tumor growth in LGG is maintained by amino acid supply and 
does not escape towards other metabolic pathways. 
With regard to identify patients who benefit from treatment the prediction of treatment 
response in individual patients would have major impact on patient care. Several 
studies suggested that histological features of LGG (fibrillary astrocytoma versus 
oligodendroglial tumors) and molecular profiles (e.g. status of loss-of-heterozygosity, 
LOH, on 1p/19q, methylation of O6-methylguanine-methyltransferase, MGMT) are 
associated with treatment response and survival. In individual patients, however, 
treatment response cannot be predicted yet [26, 27], and molecular markers are not 
implemented into clinical practice. Actually our data may lead to the concept that 
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individual patient management should be optimized by early response identification 
in addition to response prediction. We clearly demonstrate the advantage of 
molecular over structural imaging in LGG particularly with regard to the time window 
(figure 3). FET PET data may therefore assist to define the maximal duration of 
chemotherapy. Due to our small sample size we cannot draw final conclusions as to 
whether the magnitude of PET and MR responses relate to the subsequent clinical 
course and to the time until tumor progression. This has to be addressed in larger 
prospective studies. We conclude that the early identification of non-responders will 
help to minimize any negative impact of chemotherapy on quality of life. Finally, 
individually optimized treatment will also have economical impact since the costs of 
PET imaging must be weighted against the expenses of chemotherapy and the 
management of adverse effects.  
 
Acknowledgements 
This work was supported by grants of the Swiss Group for Clinical Cancer Research 
(SAKK) and by Essex Chemie AG, Luzern, Switzerland. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Wyss page 11 
 
 
 
References 
1. Schiff D, PD Brown, and C Giannini. (2007) Outcome in adult low-grade 
glioma: the impact of prognostic factors and treatment. Neurology 69:1366-
1373 
2. Brada M, L Viviers, C Abson, et al. (2003) Phase II study of primary 
temozolomide chemotherapy in patients with WHO grade II gliomas. Ann 
Oncol 14:1715-1721 
3. Hoang-Xuan K, L Capelle, M Kujas, et al. (2004) Temozolomide as initial 
treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas 
and correlation with chromosome 1p deletions. J Clin Oncol 22:3133-3138 
4. Kaloshi G, A Benouaich-Amiel, F Diakite, et al. (2007) Temozolomide for low-
grade gliomas: predictive impact of 1p/19q loss on response and outcome. 
Neurology 68:1831-1836 
5. Pouratian N, J Gasco, JH Sherman, et al. (2007) Toxicity and efficacy of 
protracted low dose temozolomide for the treatment of low grade gliomas. J 
Neurooncol 82:281-288 
6. Quinn JA, DA Reardon, AH Friedman, et al. (2003) Phase II trial of 
temozolomide in patients with progressive low-grade glioma. J Clin Oncol 
21:646-651 
7. Macdonald DR, TL Cascino, SC Schold, Jr., et al. (1990) Response criteria for 
phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 
8. Miyagawa T, T Oku, H Uehara, et al. (1998) "Facilitated" amino acid transport 
is upregulated in brain tumors. J Cereb Blood Flow Metab 18:500-509 
9. Kleihues P, DN Louis, BW Scheithauer, et al. (2002) The WHO classification 
of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-225 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Wyss page 12 
 
 
 
10. EORTC (European Organization of Research and Treatment of Cancer) 
Intergroup study 22033-26033: Primary chemotherapy with temozolomide vs. 
radiotherapy in patients with low grade gliomas after stratification for genetic 
1p loss: a phase III study (http://groups.eortc.be/brain/html/trials.html).  
11. Weckesser M, KJ Langen, CH Rickert, et al. (2005) O-(2-[18F]fluorethyl)-L-
tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl 
Med Mol Imaging 32:422-429 
12. Mikolajczyk K, M Szabatin, P Rudnicki, et al. (1998) A JAVA environment for 
medical image data analysis: initial application for brain PET quantitation. Med 
Inform (Lond) 23:207-214 
13. Wyss MT, S Hofer, M Hefti, et al. (2007) Spatial heterogeneity of low-grade 
gliomas at the capillary level: a PET study on tumor blood flow and amino acid 
uptake. J Nucl Med 48:1047-1052 
14. Husstedt HW, M Sickert, H Kostler, et al. (2000) Diagnostic value of the fast-
FLAIR sequence in MR imaging of intracranial tumors. Eur Radiol 10:745-752 
15. Tang BN, N Sadeghi, F Branle, et al. (2005) Semi-quantification of methionine 
uptake and flair signal for the evaluation of chemotherapy in low-grade 
oligodendroglioma. J Neurooncol 71:161-168 
16. Herholz K, T Holzer, B Bauer, et al. (1998) 11C-methionine PET for differential 
diagnosis of low-grade gliomas. Neurology 50:1316-1322 
17. Mandonnet E, JY Delattre, ML Tanguy, et al. (2003) Continuous growth of 
mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53:524-528 
18. Ricard D, G Kaloshi, A Amiel-Benouaich, et al. (2007) Dynamic history of low-
grade gliomas before and after temozolomide treatment. Ann Neurol 61:484-
490 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Wyss page 13 
 
 
 
19. Ribom D, M Schoenmaekers, H Engler, et al. (2005) Evaluation of 11C-
methionine PET as a surrogate endpoint after treatment of grade 2 gliomas. J 
Neurooncol 71:325-332 
20. Nuutinen J, P Sonninen, P Lehikoinen, et al. (2000) Radiotherapy treatment 
planning and long-term follow-up with [(11)C]methionine PET in patients with 
low-grade astrocytoma. Int J Radiat Oncol Biol Phys 48:43-52 
21. Voges J, K Herholz, T Holzer, et al. (1997) 11C-methionine and 18F-2-
fluorodeoxyglucose positron emission tomography: a tool for diagnosis of 
cerebral glioma and monitoring after brachytherapy with 125I seeds. 
Stereotact Funct Neurosurg 69:129-135 
22. Asano S, M Kameyama, A Oura, et al. (2007) L-type amino acid transporter-1 
expressed in human astrocytomas, U343MGa. Biol Pharm Bull 30:415-422 
23. Nawashiro H, N Otani, N Shinomiya, et al. (2006) L-type amino acid 
transporter 1 as a potential molecular target in human astrocytic tumors. Int J 
Cancer 119:484-492 
24. Roelcke U, E Radu, S Ametamey, et al. (1996) Association of rubidium and C-
methionine uptake in brain tumors measured by positron emission 
tomography. J Neurooncol 27:163-171 
25. Wienhard K, K Herholz, HH Coenen, et al. (1991) Increased amino acid 
transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J 
Nucl Med 32:1338-1346 
26. van den Bent MJ and JM Kros. (2007) Predictive and prognostic markers in 
neuro-oncology. J Neuropathol Exp Neurol 66:1074-1081 
27. Yip S, AJ Iafrate, and DN Louis. (2008) Molecular diagnostic testing in 
malignant gliomas: a practical update on predictive markers. J Neuropathol 
Exp Neurol 67:1-15 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Wyss page 14 
 
 
 
Figure Legends 
 
Fig. 1 Treatment responses of MR FLAIR (square) are compared with the active FET 
tumor volume (triangle) in patient #4 (a), #3 (b), and #5 (c). C: the increase of the 
active FET volume at 21 months was associated with tumor progression to anaplastic 
oligoastrocytoma WHO III 
 
Fig. 2 Top: Patient #3 (figure 1a). Imaging studies were done before (left), and 6, 12, 
18, 24 months after initiation of chemotherapy. Bottom: Patient #5 (figure 1c). 
Imaging studies were done before (left), and 3, 9, 15, 21 months after initiation of 
chemotherapy. At the time of clear metabolic tumor progression (21 months) a small 
increase of the MR FLAIR tumor volume was noted compared to the volume at 15 
months (25 vs. 21 ccm). No tumor gadolinium enhancement was observed. The 
increase of the active FET tumor volume (27.8 vs. 6.5 ccm) was paralleled by an 
increase of the FET uptake ratio (1.98 vs. 1.51) which is compatible with progression 
from WHO II towards WHO III. The color scale represents the tumor:cerebellum 
uptake ratio. 
 
Fig. 3 The time course of FET (triangle) and MR (square) volumes in metabolic 
responders is plotted until tumor progression or study termination (n=8, mean±SEM). 
Follow up data points: group B at 3, 9, 15 months (n = 2, 2, 1 patients), group A at 6, 
12, 18, 24 months (n = 6, 5, 4, 3 patients) 
 
Fig. 4 The metabolic response at the first FET PET follow up (ΔBaseline FET -  first 
FET response (%)) is plotted against the best MR volume response (ΔBaseline MR – 
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maximum MR response (%)). Circles: metabolic responders, triangles: non-
responders. In non-responders the MR volume at the last MR scan is taken 
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Figure 2
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Figure 3
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Table 1. Clinical and imaging data
#
(group)
histology
a
, 
resection 
type
b
gender age 
[years]
baseline T:CBL 
ratio
c
response 
type
MR
e
FET
f FET MR FET MR FET
1 (B) FIAC, pr f 49 46 29 1.24 R 96 49 - 3
2 (A) FIAC, pr m 23 52 52 1.52 R 91 6 - 12
3 (A) OA, b m 28 90 78 1.57 R 65 15 12 12
4 (A) OA, pr f 28 14 11 1.32 R 65 8 18 6
5 (B) OA, pr m 27 23 18 1.45 R 90 38 15 3
6 (A) OD, b m 34 23 29 1.64 R 39 40 12 12
7 (A) OD, pr f 45 25 27 1.40 R 33 18 18 12
8 (A) OD, pr m 36 284 273 1.33 R 102 71 - 6
9 (B) FIAC, pr m 32 44 6 1.25 NR 109 121 - -
10 (A) FIAC, b m 38 66 0 1.10 NR 99 100 - -
11 (A) OA, b m 39 79 69 1.43 NR 99 93 - -
time to best volume 
response
[months]
baseline
tumor volume
[ccm]
best volume response
 [% from baseline]
a Histology: FIAC fibrillary astrocytoma, OA oligoastrocytoma, OD oligodendroglioma.  
b Resection type:  b biopsy, pr partial resection.  
c T:CBL ratio = uptake of the active tumor volume normalized to the mean uptake of the cerebellum.  
d Response type according to FET PET follow up results (see Methods): R responding patients, NR non-responding patients.  
e MR = FLAIR sequence; f FET = active tumor volume of amino acid uptake.  
Table
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